TAGS: Skin Care
Beiersdorf has announced collaboration with Insilico Medicine, an artificial intelligence company developing end to end drug discovery pipelines. Beiersdorf will use artificial intelligence to accelerate the discovery of novel and safe active ingredients.
Partnership Aiming to Explore Bioactive Ingredients
The companies are entering a collaboration to discover novel and safe bioactive ingredients for a specific skin indication at an unparalleled pace, that will serve as the basis for developing appropriate skincare products.
“
As part of our Open Innovation culture, we are always looking for new technologies and partners with strengths that complement ours. We are delighted to now be working with Insilico Medicine as a veritable expert when it comes to artificial intelligence,” commented Dr. May Shana’a, Senior corporate vice president, research and development, Beiersdorf.
Analyzing New Molecules Using AI
New molecules for a specific skin indication to be generated and analyzed using next-generation artificial intelligence developed by Insilico Medicine. This enables the company to cater even better to the consumers’ yet unmet skincare needs.
“
We firmly believe there is a great potential in this collaboration. We worked with many consumer companies in the past and in my opinion, Beiersdorf became an undisputed leader in the area of skin research as well as in digital technologies in recent decades,” commented Alex Zhavoronkov, CEO of Insilico Medicine.
“
We are delighted that they have recognized the potential of artificial intelligence early on and hope to demonstrate the power of AI going forward in our collaboration,” Zhavoronkov added.
Source: Beiersdorf